University of California, Los Angeles
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).
University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.
University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.
Top-decile sponsor footprint
University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
897 total, page 2 of 18
Effect of Daily Mixed Spice Consumption on Memory Function
NCT06889961
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
NCT06337942
NIRS for the Diagnosis of Myofascial Pelvic Pain
NCT07181447
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
NCT05971758
Polyphenols and Cognitive Decline
NCT06507254
Work Time Schedule Changes for Nurse Managers
NCT06406478
An Integrated Intervention Using a Pill Ingestible Sensor System
NCT06480578
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
NCT06617312
Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
NCT06668922
Promoting Early Intervention Timing and Attention to Language
NCT05853861
Comparing Surgical and Endovascular Arteriovenous Fistula Creation
NCT05654103
Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
NCT06162884
Cannabidiol for Reducing Cigarette Use
NCT06218056
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
NCT06597942
Thiamine Intervention and Coronary Artery Bypass Grafting
NCT06326996
Reward Processing and Exposure Therapy for Social Anxiety Disorder
NCT06776991
Unconscious Reduction of Fear Through Decoded Neuro-Reinforcement
NCT06420557
Starting Technology in At Risk Type 1 Diabetes Study
NCT06453928
Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry
NCT04529031
Evaluation of AI Cost Prediction Model to Enroll Patients in Complex Care Management Program
NCT06916247
Type 2 Diabetes and Blood Brain Barrier Improvement
NCT06322212
TEE and Dysphagia in Lung Transplantation
NCT06089434
Impact of Prebiotics in Ulcerative Colitis
NCT06495658
Emergency Medicine Peer Outreach Worker Engagement for Recovery
NCT06320015
Antibiotic Tumescent For Chronic Wounds
NCT06327113
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
NCT05778591
Mindful Self-Compassion to Address PTSD and Substance Use in Unhoused Women
NCT06646692
Phenotyping Response to Spinal Cord Stimulation in Chronic Low Back Pain
NCT06310226
Effects of Acupuncture on Symptoms of Stable Angina
NCT06311461
Role of Race in Nutritional Approach in Men on ADT
NCT06682390
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
NCT06073886
Exploring, Predicting, and Intervening on Long-term Viral Suppression Electronically
NCT06370780
Motivation for IV Alcohol Self-Administration in Humans
NCT06494891
Endotypic Traits and Obstructive Sleep Apnea Surgery
NCT05953610
Optimizing Treatment of Adhesive Small Bowel Obstruction
NCT06182319
Beacon Sensors and Telerehabilitation to Assess and Improve Use of Devices (BeST-AID) for Low Vision
NCT06107881
Pain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy
NCT06189781
Family Intervention to Prevent Childhood Obesity
NCT05606731
BrainWeighve App Feasibility Study
NCT05530538
Report Cards and Feedback for PCCE
NCT06155292
Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty
NCT04717869
Genicular Artery Embolization Vs Observation for Symptomatic Knee Osteoarthritis
NCT04682652
Probiotic Intervention Study
NCT06030362
Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression
NCT05329441
Testing a Self-management Intervention in HIV+ Asian Pacific Americans
NCT04353739
Photobiomodulation for Lower Back Pain Post Spinal Fusion and Decompression Surgery
NCT06282770
Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode
NCT05890183
Comparison of Artificial Disc Implants in Cervical Disc Arthroplasty
NCT05701059
Forehead Temperature-Regulating Therapy for Insomnia in Adults With Tourette's Disorder
NCT05499741
Project 2: Optimizing Engagement and Outcomes in STAND Digital Therapy
NCT05908565
What is open in the University of California, Los Angeles pipeline
158 recruiting of 897 indexed (18% open); 622 completed (69%).
Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).
Top condition: Depression (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, Los Angeles: open-pipeline peers nationwide
Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 897 trials (± recruiting share)
- Indiana University · 890 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 18% open enrollment (± trial volume)
- ConvaTec · 18% recruiting · 17 trials
- Endologix · 18% recruiting · 17 trials
- National Institute on Deafness and Other Communication Disorders (NIDCD) · 18% recruiting · 34 trials
- NICHD Pelvic Floor Disorders Network · 18% recruiting · 17 trials
Related
What to do with this University of California, Los Angeles page
897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.
- 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of California, Los Angeles pipeline card: 897 registered trials from official public datasets.Report a data error.